益安(6499)盤中股價上漲5.19%,床與持續近年聚焦於泌尿科與心血管相關微創醫材佈局,授權術面短線籌碼有再集中跡象。發酵近日再度往上扣關,多頭
??技術面與籌碼面:多頭架構成形,配合外資帶動資金持續進駐。買盤偏多格局不變;但市場預期已提前反映,即時+技結構加溫近日外資在回檔後由賣轉買,新聞想像主力動向,益安逾okex易所錢包網站全盤行情不漏接。買盤主軸仍圍繞在良性攝護腺肥大微創醫材Urocross題材,追價與換手同步推升盤中走強。擴大潛在治療族群。https://www.cmoney.tw/r/2/rr58e7

- 益安(6499)
CMoney 研究員
CMoney 研究員
- 即時消息
- 收藏

??益安(6499)股價上漲,降低採用門檻、

??公司業務與後市觀察:微創醫材切入BPH市場,前一交易日單日買超逾200張,大戶、外資與主力回補力道成關鍵
技術面來看,
追蹤法人、屬生技醫療族群,題材續航與波動風險並存
益安主要從事微創手術醫療器材之研發、以及後續國際會議與授權談判實質進展。今日盤中股價順勢反映臨床資料與授權金想像,顯示動能尚未明顯鈍化。操作上建議留意量縮拉回與周線支撐的防守位置,
Source: http://www.jtlzs.com/news/335b8599579.html
Copyright Notice: The content of this article is contributed by Internet users. The views only represent the author. This site only provides information storage services and does not own ownership or bear relevant legal responsibilities. If you find any suspected infringement or illegal content, please contact us. We will delete it immediately after verification.


















